Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFI205 first-in-human phase 1/2a study in systemic autoimmune rheumatic diseases
2026-526672-24-00Phase 2Authorised
- Sponsor
- Diabetes Free
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of DFI205 in autoimmune rheumatic diseases (ARDs), sponsored by Diabetes Free. Planned start Oct 2026; status: authorised.
02
Drugs
DFI205
03
Conditions
autoimmune rheumatic diseases (ARDs)
Beyond the preview
Go deeper on 2026-526672-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526672-24-00.